WO2007073643A1 - Agent de couplage ultrasonore, son procede de preparation et recipient le contenant - Google Patents

Agent de couplage ultrasonore, son procede de preparation et recipient le contenant Download PDF

Info

Publication number
WO2007073643A1
WO2007073643A1 PCT/CN2006/001714 CN2006001714W WO2007073643A1 WO 2007073643 A1 WO2007073643 A1 WO 2007073643A1 CN 2006001714 W CN2006001714 W CN 2006001714W WO 2007073643 A1 WO2007073643 A1 WO 2007073643A1
Authority
WO
WIPO (PCT)
Prior art keywords
coupling agent
ultrasonic coupling
agent according
ultrasonic
carbomer
Prior art date
Application number
PCT/CN2006/001714
Other languages
English (en)
Chinese (zh)
Inventor
Yunbo Tian
Zhibiao Wang
Jin Bai
Original Assignee
Chongqing Haifu (Hifu) Technology Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Haifu (Hifu) Technology Co., Ltd. filed Critical Chongqing Haifu (Hifu) Technology Co., Ltd.
Publication of WO2007073643A1 publication Critical patent/WO2007073643A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/225—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
    • A61B17/2251—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves characterised by coupling elements between the apparatus, e.g. shock wave apparatus or locating means, and the patient, e.g. details of bags, pressure control of bag on patient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
    • G01N29/22—Details, e.g. general constructional or apparatus details
    • G01N29/28—Details, e.g. general constructional or apparatus details providing acoustic coupling, e.g. water
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/225—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
    • A61B17/2251—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves characterised by coupling elements between the apparatus, e.g. shock wave apparatus or locating means, and the patient, e.g. details of bags, pressure control of bag on patient
    • A61B2017/2253—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves characterised by coupling elements between the apparatus, e.g. shock wave apparatus or locating means, and the patient, e.g. details of bags, pressure control of bag on patient using a coupling gel or liquid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/42—Details of probe positioning or probe attachment to the patient
    • A61B8/4272—Details of probe positioning or probe attachment to the patient involving the acoustic interface between the transducer and the tissue
    • A61B8/4281—Details of probe positioning or probe attachment to the patient involving the acoustic interface between the transducer and the tissue characterised by sound-transmitting media or devices for coupling the transducer to the tissue

Definitions

  • the invention belongs to the technical field of ultrasonic treatment, and particularly relates to an ultrasonic therapeutic coupling agent, a preparation method thereof and a packaging device. Background technique
  • the couplant is a substance that is coupled between the ultrasonic head and the skin to facilitate filling of voids and to prevent interfacial reflection by air layer, so as to facilitate the passage of ultrasonic energy (Feng Ruo, Wang Zhiwei, editor-in-chief) Therapeutics. 1st edition, Beijing, Science and Technology Literature Publishing House. 2002; 11: 206).
  • the reciprocating movement is significantly reduced, causing the couplant to be lost on the non-horizontal treatment surface, resulting in a decrease in coupling effect and a decrease in lubrication performance.
  • the friction between the ultrasonic treatment head and the contact surface is also increased, not only for the doctor.
  • the inconvenience of the treatment operation also increases the risk of rubbing on the treated surface; since the therapeutic ultrasound energy does not pass well through the surface of the treatment area, there is a risk of burns on the surface of the treatment area.
  • due to therapeutic ultrasound especially focused ultrasound inevitably stimulates the subcutaneous nerve to produce pain, but ordinary ultrasound coupling
  • the agent has no analgesic effect.
  • the viscosity also changes at different ambient temperatures.
  • distilled water When distilled water is used as the ultrasonic coupling agent, it is generally used in two cases. One is to immerse the treatment surface and the treatment head in distilled water. This coupling method works well, but it is not easy to implement in general treatment. The second is to maintain coupling by using distilled water between the ultrasound treatment head and the treatment surface, but because the treatment surface is often not horizontal, such as treatment of some gynecological diseases, such as leukoplakia, chronic cervicitis, etc., due to these diseases
  • the anatomical position can only spray distilled water directly in the target area, and the distilled water has poor viscosity and easy to flow around. It requires a large amount of running water to fill and can not couple the ultrasonic head and the treatment surface well, thus causing pollution to the operating environment. It brings a lot of inconvenience to doctors and patients, and it has no painkilling effect.
  • the technical problem to be solved by the present invention is to provide a good acoustic performance, stability, safety, and the ability to maintain the reciprocating motion of the treatment head and at different ambient temperatures in view of the deficiencies of the prior art ultrasonic coupling agent.
  • Ultrasonic therapeutic coupling agent requiring viscosity, antibacterial and analgesic effect, preparation method thereof, packaging method and application.
  • the technical solution adopted to solve the technical problem of the present invention is that the ultrasonic coupling agent contains the following components by weight:
  • ultrasonic coupling agent of the present invention further comprises:
  • Humectant 0.5 ⁇ 10% ;
  • ultrasonic coupling agent of the present invention further comprises:
  • Antibiotic drugs 0.1 ⁇ 2% ;
  • ultrasonic coupling agent of the present invention further comprises:
  • Anesthetic drug 0.1 ⁇ 2% The function of the humectant is to maintain a sufficient water content in the coupling agent; metronidazole is a white or milky white crystalline powder, the product has anti-anaerobic effect, strong killing of trichomoniasis, can reduce or avoid surgical infection;
  • the agent is selected from the group consisting of polyhydric alcohols such as polyethylene glycol (PEG), glycerin, propylene glycol, preferably medicinal polyethylene glycol (PEG);
  • the antibiotic drugs are macrolide-like antibiotics such as spiramycin, clarithromycin
  • the anesthetic is an amide or ester local anesthetic such as procaine, bupivacaine and lidocaine, and the solvent is distilled water.
  • Carbomer's chemical name cross-linked polyacrylic acid resin, molecular structure: - [-CH2-CH-]n-COOH.
  • the preparation method of the above ultrasonic coupling agent specifically includes the following steps:
  • Step (2) Degassing cans for disinfection.
  • the carbomer in step (2) can be swollen in the solvent by heating or changing the pH (such as adding NaOH).
  • Step (1) further comprises weighing 0.1 ⁇ 2% of metronidazole, 0.5-10% of humectant, 0.1 ⁇ 2% of antibiotic drug, and step (2) swelling carbomer to dissolved methotrexate
  • the antibiotic drug and the humectant are added to the solution of the step (2) and stirred uniformly. Further, the antibiotic drug is first dissolved in the humectant, and then added to the solution of the step (2) and stirred uniformly.
  • the step (1) further includes weighing 0.1 to 2% of the anesthetic, adding the anesthetic to the solution of the step (2) or the solution of the step (2) and the mixture of the antibiotic and the moisturizer.
  • the solvent is distilled water
  • metronidazole is a white or milky white crystalline powder.
  • Antibiotic drugs use macrolide antibiotics, humectants use polyols, and anesthetics use amide or ester local anesthetics.
  • the carbomer is swollen in distilled water and heated to 70 ⁇ in a water bath to accelerate the swelling process.
  • the solid tablets of the macrolide antibiotics are ground into fine powder and dissolved in polyethylene glycol, fully stirred and dissolved, and then filtered. Mix the filtrate with the dissolved carbomer and mix well. Add the anesthetic and mix well. Adjust the enthalpy to 5.5 8.0. Stir well.
  • the carbomer can be swollen in the solvent by heating or changing the enthalpy (for example, using NaOH); when deaerating, the vacuum or centrifugal degassing can be used.
  • the enthalpy for example, using NaOH
  • the antibiotic drug can be uniformly dispersed in the couplant and stabilized by a special treatment method (that is, the drug is dispersed and dissolved in a humectant by means of an ultrasonic pulverizer and then subjected to high pressure filtration).
  • the ultrasonic coupling agent prepared according to the above method may be additionally added with an auxiliary material as needed.
  • the resulting ultrasonic couplant is used for convenient and safe use.
  • the present invention also provides a package container for an ultrasonic couplant, the device comprising a container for the ultrasonic couplant, the container being provided with a single sterilized, separately packaged catheter. Since the catheter is in direct contact with the skin or mucosal surface, the front end of the catheter is blunt in order to protect the skin or mucosal surface.
  • a preferred container for the ultrasonic coupling agent can be a spring bottle or a syringe.
  • the ultrasonic coupling agent provided by the invention has the advantages of good carbomer thickening effect, strong shear resistance and permanent stability at high viscosity, and polyethylene glycol (PEG) can be used as a moisturizer, and Dissolves the action of the active ingredients of antibiotics.
  • the invention can make the treatment head move smoothly, has sufficient coupling, reduces the pain and discomfort of the treatment, has a clean treatment surface, and has anti-infection effect after treatment, and can be widely applied to ultrasonic treatment, especially for leukoplakia and chronic diseases. Diseases such as cervicitis can play a good coupling role.
  • an ultrasonic treatment coupling agent observed by physical detection and animal efficacy experiments The effect of ultrasound treatment on animals.
  • the results show that the couplant has a sound velocity of 1520 ⁇ 1620m / s at 35 ° C ; acoustic impedance (1.5 ⁇ 1.7) X 10 6 Pa ⁇ s / m; sound attenuation coefficient 0.05dB / (cm ⁇ MHz); Viscosity (25 ° C): 15 ⁇ 80Pa / s; PH: 5.5 ⁇ 8. Apply directly to rabbit eyes and no irritating or toxic side effects were observed.
  • the ultrasonic coupling agent of the invention adopts the synthetic high-molecular substance carbomer as a matrix, adds antibiotic drugs by a special drug dissolution method, controls the viscosity of the proper coupling agent, and applies the unique packaging disinfection method to the ultrasonic treatment, which is safe and stable. , the advantages of good acoustic performance. Ultrasound treatment with this couplant can effectively avoid skin burns caused by the couplant itself. The ultrasonic treatment head moves smoothly, the coupling is sufficient, the treatment surface is clean, the anti-infection effect after treatment, and the raw materials are abundant. The cost is low, the production process is simple, hygienic and safe, and the packaging is easy to use. In the course of ultrasound treatment of gynecological diseases, the ultrasonic therapeutic couplant of the present invention can be a suitable coupling medium.
  • the matrix of the present invention can be varied in concentration depending on the temperature of the use environment, resulting in a consistent viscosity performance at various ambient temperatures.
  • Figure 1 is a schematic view of a package of an ultrasonic coupling agent of the present invention
  • the ultrasonic coupling agent of this embodiment is composed of the following weight percentages: carbomer 0.5%, metronidazole 0.1%, Polyethylene glycol 0.5%, spiramycin 0.1% procaine 0.1%, distilled water 98.7%.
  • Preparation method Take carbomer to swell in distilled water which has dissolved metronidazole, and simultaneously heat it to 70 °C in water bath to accelerate the swelling process; take the spiromycin solid tablet into fine powder and dissolve it in the polymer by ultrasonic pulverizer In the ethylene glycol, fully stirred and dissolved, and then filtered under high pressure. The filtrate is mixed with the dissolved carbomer and stirred evenly. Then add procaine. Adjust the pH value to 5.5 8.0 with NaOH during the mixing process, and mix well; The tank can be degassed by centrifugal degassing after being filled in a pneumatic tank.
  • the gas content can be controlled by the time and speed of centrifugation, and generally no fine bubbles can be seen by the naked eye. At this point, the preparation process is completed.
  • the ultrasonic coupling agent prepared in this embodiment is nearly transparent and water-soluble, and contains only or no gel which is invisible to the naked eye and is incapable of detecting microbubbles and insoluble foreign substances. Suitable for winter or below 10 °C. The effects of ultrasonic treatment on animals were observed by physical test and animal efficacy test.
  • the technical performance index of the couplant was 35 ⁇
  • the sound performance was: 1520 ⁇ 1620 m / s; Impedance (1.5 ⁇ 1.7) X 10 6 Pa - s/m; Sound attenuation coefficient 0.05dB/(cm ⁇ MHz); Viscosity (25.C): 15 ⁇ 80Pa/s; PH: 5.5 ⁇ 8. Apply directly to rabbit eyes without irritating or toxic side effects.
  • the ultrasonic couplant packaging container comprises a bottle body 2 and a catheter 1.
  • the bottle body has a spring body 4, and the catheter 1 is disposed at the front end of the bottle body.
  • the material of the catheter 1 is non-toxic.
  • a flexible hose that retains its original shape. The length is 8 ⁇ 15cm, the front end is blunt, and it can directly contact the skin or mucous membrane surface. It is a single-use, sterilized and individually packaged catheter.
  • the ultrasonic coupling agent prepared in this embodiment is filled in the disposable spring bottle body and used after being sterilized by radiation.
  • Example 2
  • the ultrasonic coupling agent of the present embodiment is composed of the following weight ratio: carbomer 10%, metronidazole 2%, Polyethylene glycol 10%, clarithromycin 2%, bupivacaine 2%, distilled water 74%.
  • Preparation method Take carbomer to swell in distilled water which has dissolved metronidazole, and heat it to 70 °C with water bath to accelerate the swelling process; take clarithromycin solid tablets into fine powder and dissolve in polyethylene glycol , thoroughly stir and dissolve, filter, take the filtrate and mix with the dissolved carbomer and mix well, then add bupivacaine to mix, adjust the PH value to 5.5 ⁇ 8.0, fully stir evenly; use the canned air tank after canning Centrifugal degassing is used to degas, and the gas content in the centrifuge can be controlled by the time and speed of centrifugation. Generally, fine bubbles are not visible to the naked eye. At this point, the preparation process is completed.
  • the ultrasonic coupling agent prepared in this embodiment is nearly transparent and water-soluble, and contains only or no gel which is invisible to the naked eye and is incapable of detecting microbubbles and insoluble foreign substances. Suitable for summer or above 30 °C. The effects of ultrasound treatment on animals were observed by physical testing and animal efficacy experiments.
  • the ultrasonic couplant packaging container comprises a cylinder 3, a conduit 1, the cylinder 3 is a syringe container, the front part is a container cylinder 5, the rear part is a push handle 6, and the duct 1 is arranged in a container cylinder
  • the front end of the 5, the material of the catheter 1 is non-toxic, and the flexible hose can maintain the original shape.
  • the catheter material is a non-toxic, flexible hose that retains its original shape. It is 8 ⁇ 15cm long and has a rounded front end. It can directly contact the skin or mucous membrane surface. It is a disposable, individually packaged catheter.
  • the ultrasonic coupling agent prepared in this embodiment is filled in the above-mentioned disposable syringe type container and used after being sterilized by radiation.
  • the ultrasonic coupling agent of this embodiment is composed of the following weight percentages: carbomer 5%, metronidazole 1%, poly 5% of ethylene glycol, 1% of macrolide antibiotics, 1% of anesthetics, and 87% of distilled water.
  • Preparation method taking carbomer swelled in distilled water which has dissolved metronidazole, and simultaneously heated to 70 in a water bath to accelerate the swelling process; taking the solid tablets of medimycin into fine powder and dissolving in polyethylene glycol, After thoroughly stirring and dissolving, filter, take the filtrate and mix with the dissolved carbomer and mix well, then add lidocaine to mix, adjust the PH value to 5.5 8.0, stir well; use the pneumatic canning method to use the centrifugal degassing after centrifugation In the manner of degassing, the gas content in the centrifuge can be controlled by the time and rotation speed of the centrifugation, and generally no fine bubbles can be seen by the naked eye.
  • the ultrasonic coupling agent prepared in this embodiment is nearly transparent and water-soluble, and contains only or no microbubbles which are not easily noticeable to the naked eye, and gels which have no insoluble foreign matter. Suitable for spring and autumn or 10 ⁇ 30 °C environment. The effects of ultrasound treatment on animals were observed by physical testing and animal efficacy experiments.
  • the ultrasonic couplant packaging container comprises a cylinder 3, a conduit 1, the cylinder 3 is a syringe container, the front part is a container cylinder 5 , the rear part is a push handle 6 , and the duct 1 is arranged in a container cylinder
  • the front end of the 5, the material of the catheter 1 is non-toxic, and the flexible hose can maintain the original shape.
  • the catheter material is non-toxic, flexible hose that can maintain the original shape, the length is 8 ⁇ 15cm, the front end is blunt, can directly contact the skin or mucous membrane surface, and is a single-time disinfected and individually packaged catheter.
  • the ultrasonic coupling agent prepared in this embodiment is filled in the above-mentioned disposable syringe type container and used after being sterilized by radiation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acoustics & Sound (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'agent de couplage ultrasonore comprend entre 0,5 et 10 % de carbopol, entre 74 et 983 % de solvant, entre 0,1 et 2 % de métronidazole, entre 0,5 et 10 % d'humidifiant, entre 0,1 et 2 % d'antibiotique, entre 0,1 et 2 % d'anesthésiant, les teneurs étant exprimés en poids. L'agent de couplage est préparé par (1) apport des composants, (2) mélange homogène ou dissolution, (3) réglage du pH entre 5,5 et 8,0, (4) mélange homogène par agitation et (5) stérilisation par déventilation du réservoir. Le récipient comprend un conteneur et un tube. Le tube présente une extrémité avant mousse, alors que le récipient adopte la forme d'une bouteille de pompage ou d'une seringue. L'agent de couplage fait preuve d'une viscosité contrôlée. Il est sûr et stable, est utilisé dans la recherche ultrasonore sans causer de brûlures cutanées et est en mesure de tuer les bactéries et d'éviter la surinfection, tout en facilitant le glissement du transducteur sur la peau.
PCT/CN2006/001714 2005-12-28 2006-07-17 Agent de couplage ultrasonore, son procede de preparation et recipient le contenant WO2007073643A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200510023048.5 2005-12-28
CN2005100230485A CN1990048B (zh) 2005-12-28 2005-12-28 一种超声治疗耦合剂及其制备方法和包装装置

Publications (1)

Publication Number Publication Date
WO2007073643A1 true WO2007073643A1 (fr) 2007-07-05

Family

ID=38212728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2006/001714 WO2007073643A1 (fr) 2005-12-28 2006-07-17 Agent de couplage ultrasonore, son procede de preparation et recipient le contenant

Country Status (2)

Country Link
CN (1) CN1990048B (fr)
WO (1) WO2007073643A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101797391A (zh) * 2010-03-12 2010-08-11 苏州御芙蓉日化有限公司 一次性杀菌型医用超声耦合剂及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101513554B (zh) * 2008-02-21 2011-09-07 重庆海扶(Hifu)技术有限公司 一种智能型仿组织超声体模及其制作方法
CN102266340B (zh) * 2010-06-04 2014-05-14 梁建琴 一种抗结核的凝胶制剂
CN104096321B (zh) * 2014-07-08 2017-06-16 深圳市普罗惠仁医学科技有限公司 用于高强度聚焦超声治疗系统的耦合液供给设备
CN106035317A (zh) * 2016-06-23 2016-10-26 于甜甜 一种b超室用消毒液

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002221A (en) * 1972-09-19 1977-01-11 Gilbert Buchalter Method of transmitting ultrasonic impulses to surface using transducer coupling agent
RO106662B1 (ro) * 1990-08-07 1993-06-30 Raisa Motocescu Compoziție hidrofila, sonotransparenta
FR2770402A1 (fr) * 1997-11-05 1999-05-07 Pierre Cohen Gel de conduction ultrasonore pour echographie, doppler et examens electrocardiographiques presentant des proprietes antiseptiques
CN2421960Y (zh) * 2000-04-29 2001-03-07 胡根生 超声诊断辅料包

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087016A (zh) * 1992-11-14 1994-05-25 鞍山钢铁公司 医用超声耦合剂的制备方法
US20020061864A1 (en) * 1994-09-22 2002-05-23 Geda International Marketing Company Ltd. Antiseptic spermicidal composition and means for its application

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002221A (en) * 1972-09-19 1977-01-11 Gilbert Buchalter Method of transmitting ultrasonic impulses to surface using transducer coupling agent
RO106662B1 (ro) * 1990-08-07 1993-06-30 Raisa Motocescu Compoziție hidrofila, sonotransparenta
FR2770402A1 (fr) * 1997-11-05 1999-05-07 Pierre Cohen Gel de conduction ultrasonore pour echographie, doppler et examens electrocardiographiques presentant des proprietes antiseptiques
CN2421960Y (zh) * 2000-04-29 2001-03-07 胡根生 超声诊断辅料包

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 1994-277234(34), XP003014890 *
DATABASE WPI Derwent World Patents Index; AN 1999-290517(25), XP003014889 *
LI W. ET AL.: "Research and development on medical coupling gel used In ultrasonic diagnosis (CHINESE)", PROGRESS IN PHARMACEUTICAL SCIENCES, vol. 23, no. 5, 1999, pages 306 - 307 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101797391A (zh) * 2010-03-12 2010-08-11 苏州御芙蓉日化有限公司 一次性杀菌型医用超声耦合剂及其制备方法
CN101797391B (zh) * 2010-03-12 2012-01-25 苏州御芙蓉日化有限公司 一次性杀菌型医用超声耦合剂及其制备方法

Also Published As

Publication number Publication date
CN1990048A (zh) 2007-07-04
CN1990048B (zh) 2010-11-10

Similar Documents

Publication Publication Date Title
KR102145435B1 (ko) 졸-겔 폴리머 복합체 및 이의 용도
RU2379025C2 (ru) Противоинфекционные композиции в виде гидрогеля
JP7123971B2 (ja) 乳腺炎を処置する際に使用する動物用組成物、及び関連方法
JP2007512410A (ja) 皮膚接着性ヒドロゲル
JPH07500035A (ja) 水性ゲル傷用包帯剤およびパッケージ
CN101716354B (zh) 一种超声耦合剂
CN101664562A (zh) 创伤修复水凝胶材料及制备方法
WO2007073643A1 (fr) Agent de couplage ultrasonore, son procede de preparation et recipient le contenant
CN102091158B (zh) 一种治疗风湿骨病的中药凝胶制剂
TWI344850B (fr)
CN102580121B (zh) 一种医用消毒耦合剂
CN110269835A (zh) 一种卡波姆妇科抑菌修复性凝胶及其制备方法
EP2726112B1 (fr) Pulvérisation de milieu de couplage ultrasonore
CN106109587A (zh) 一种修复女性阴道微生态平衡的药物组合物
CN106620734B (zh) 一种无菌医用超声耦合贴片及其制备方法
CN102266340B (zh) 一种抗结核的凝胶制剂
CN110693814A (zh) 一种兽用替米考星纳米凝胶乳房灌注剂及其制备方法
CN108578749A (zh) 一种可载药缓释的医用复合柚皮果胶海绵敷料及其制备方法和应用
CN107638573B (zh) 一种抗菌型医用超声耦合剂及其制备方法
RU2331441C1 (ru) Гипергазированное и гиперосмотическое антисептическое средство
CN112022879A (zh) 一种妇科阴道黏膜损伤及创伤修复溶胶液及其制作方法
CN109675068A (zh) 一种具有消毒功能的医用超声耦合剂及其制备方法
CN101536995B (zh) 一种高吸液可溶性释药外用避孕膜
CN105997849B (zh) 水溶性妇科凝胶及其制备方法
EP1231897A2 (fr) Preparations de medicaments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06753151

Country of ref document: EP

Kind code of ref document: A1